1-phenyl-2-(trifluoromethyl)-1H-imidazole | 1268167-75-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-phenyl-2-(trifluoromethyl)-1H-imidazole
• 英文别名: 1-phenyl-2-(trifluoromethyl)imidazole
• CAS: 1268167-75-4
• 化学式: C₁₀H₇F₃N₂
• 分子量: 212.174
• InChiKey: XIMIYTAAKOGDLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-phenyl N’-propargyl 2-trifluoromethylamidine 在 bismuth(III) chloride 、 potassium tert-butylate 、 氧气 、 苯酚 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 6.0h， 生成 1-phenyl-2-(trifluoromethyl)-1H-imidazole
  参考文献：
  名称：

  Bi(iii)-catalyzed aminooxygenation of propargyl amidines to synthesize 2-fluoroalkyl imidazole-5-carbaldehydes and their decarbonylations

  摘要：

  Bi(iii)催化的氨氧化反应首次被用于合成2-氟烷基咪唑-5-甲醛，这些化合物在存在KOt-Bu的情况下可以高效脱羰基。

  DOI：

  10.1039/d0cc02143a

文献信息

• [EN] NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS COMME INHIBITEURS DE LA KINASE RÉARRANGÉE AU COURS DE LA TRANSFECTION (RET)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2016037578A1

  公开（公告）日：2016-03-17

  This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

  这项发明涉及一种新型化合物，这些化合物是重排转位过程中的抑制剂（RET）激酶，包含它们的药物组合物，它们的制备方法，以及它们在治疗中的使用，单独或结合使用，用于规范胃肠敏感性、蠕动和/或分泌以及/或腹部紊乱或疾病和/或与RET功能障碍相关的疾病或调节RET活性可能具有治疗益处的治疗，包括但不限于所有分类的肠易激综合征（IBS），包括以腹泻为主、以便秘为主或交替排便模式、功能性腹胀、功能性便秘、功能性腹泻、未特指的功能性肠道障碍、功能性腹痛综合征、慢性特发性便秘、功能性食管障碍、功能性胃十二指肠障碍、功能性肛门疼痛、炎症性肠病、非小细胞肺癌、肝细胞癌、结肠癌、髓样甲状腺癌、滤泡性甲状腺癌、间变性甲状腺癌、乳头状甲状腺癌、脑肿瘤、腹腔癌、实体肿瘤、其他肺癌、头颈癌、神经胶质瘤、神经母细胞瘤、冯·希普-林道氏综合征和肾肿瘤、乳腺癌、输卵管癌、卵巢癌、移行细胞癌、前列腺癌、食管和食管胃交界处癌症、胆道癌、腺癌，以及任何具有增加RET激酶活性的恶性肿瘤。
• Copper-Mediated Trifluoromethylation of Heteroaromatic Compounds by Trifluoromethyl Sulfonium Salts
  作者：Cheng-Pan Zhang、Zong-Ling Wang、Qing-Yun Chen、Chun-Tao Zhang、Yu-Cheng Gu、Ji-Chang Xiao

  DOI：10.1002/anie.201006823

  日期：2011.2.18

  Copper is king! A convenient method for the synthesis of trifluoromethylated heteroaromatic compounds under mild conditions has been developed based on the observation that 1 can be reduced by certain metals (see scheme). Substrate 1 is assumed to be reduced by copper via a single‐electron transfer mechanism, and CuCF3 is the most probable intermediate in this reaction. DMF=N,N‐dimethylformamide, Tf=triflate

  铜为王！基于观察到某些金属可以还原1的现象，开发了一种在温和条件下合成三氟甲基化杂芳族化合物的简便方法（参见方案）。假设通过单电子转移机理将底物1还原为铜，而CuCF 3是该反应中最可能的中间体。DMF = N，N-二甲基甲酰胺，Tf =三氟甲磺酸。
• KINASE MODULATORS
  申请人：Exelixis, Inc.

  公开号：EP1581309A2

  公开（公告）日：2005-10-05
• EP1581309A4
  申请人：——

  公开号：EP1581309A4

  公开（公告）日：2009-07-29
• NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP3191449A1

  公开（公告）日：2017-07-19